Hemab Therapeutics Holdings, Inc 10-Q for FY2026 Q3
Hemab Therapeutics Holdings, Inc. (COAG)
10-Q
2026-11-10
For: 2026-09-30
View Original
Added on
November 10, 2026
About this 10-Q
Hemab Therapeutics Holdings, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Hemab Therapeutics Holdings, Inc. initiated SOLARA Phase 3 of sutacimig in November 2026. Its nine-month net loss was $74.1 million, while cash and marketable securities totaled $430.2 million as of September 30, 2026, funding operations into 2029. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $27.3M
- compared with a net loss of $17.07M a year earlier
- Diluted EPS
- -$0.58
- compared with -$18.04 a year earlier